OTEZLA XR Drug Patent Profile

Which patents cover Otezla Xr, and what generic alternatives are available?

Otezla Xr is a drug marketed by Amgen Inc and is included in one NDA. There are five patents protecting this drug.

This drug has ninety-five patent family members in twenty-seven countries.

The generic ingredient in OTEZLA XR is apremilast. There are twenty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the apremilast profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Otezla Xr

A generic version of OTEZLA XR was approved as apremilast by ALKEM LABS LTD on September 21^st, 2021.

Summary for OTEZLA XR

International Patents:	95
US Patents:	5
Applicants:	1
NDAs:	1
Clinical Trials:	51
Drug Prices:	Drug price information for OTEZLA XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OTEZLA XR
DailyMed Link:	OTEZLA XR at DailyMed

See drug prices for OTEZLA XR

Recent Clinical Trials for OTEZLA XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
SFA Therapeutics	PHASE2
Wake Forest University Health Sciences	Early Phase 1
Amgen	Early Phase 1

See all OTEZLA XR clinical trials

US Patents and Regulatory Information for OTEZLA XR

OTEZLA XR is protected by nine US patents and four FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amgen Inc	OTEZLA XR	apremilast	TABLET, EXTENDED RELEASE;ORAL	210745-001	Aug 29, 2025		RX	Yes	Yes	11,752,129		Y
Amgen Inc	OTEZLA XR	apremilast	TABLET, EXTENDED RELEASE;ORAL	210745-001	Aug 29, 2025		RX	Yes	Yes	10,092,541
Amgen Inc	OTEZLA XR	apremilast	TABLET, EXTENDED RELEASE;ORAL	210745-001	Aug 29, 2025		RX	Yes	Yes
Amgen Inc	OTEZLA XR	apremilast	TABLET, EXTENDED RELEASE;ORAL	210745-001	Aug 29, 2025		RX	Yes	Yes	11,969,409		Y
Amgen Inc	OTEZLA XR	apremilast	TABLET, EXTENDED RELEASE;ORAL	210745-001	Aug 29, 2025		RX	Yes	Yes	12,427,136
Amgen Inc	OTEZLA XR	apremilast	TABLET, EXTENDED RELEASE;ORAL	210745-001	Aug 29, 2025		RX	Yes	Yes
Amgen Inc	OTEZLA XR	apremilast	TABLET, EXTENDED RELEASE;ORAL	210745-001	Aug 29, 2025		RX	Yes	Yes

International Patents for OTEZLA XR

See the table below for patents covering OTEZLA XR around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3188745	DOSAGE D'APRÉMILAST POUR LE TRAITEMENT DE MALADIES AMÉLIORÉES PAR L'INHIBITION DE PDE4 (DOSAGE TITRATION OF APREMILAST FOR THE TREATMENT OF DISEASES AMELIORATED BY PDE4 INHIBITION)
World Intellectual Property Organization (WIPO)	2016025686
Argentina	125988	FORMULACIONES DE APREMILAST
Australia	2022280939	FORMULATIONS OF APREMILAST
Brazil	112023024564	Formulações de apremilast
Canada	3216640	FORMULATIONS D'APREMILAST (FORMULATIONS OF APREMILAST)
China	117597106	阿普斯特配制品 (Apremilast formulations)

Supplementary Protection Certificates for OTEZLA XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2962690	300994	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT
2962690	LUC00125	Luxembourg		PRODUCT NAME: APREMILAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/14/981 20150116
2962690	122019000070	Germany		PRODUCT NAME: APREMILAST ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/981 20150115
2962690	CA 2019 00033	Denmark		PRODUCT NAME: APREMILAST ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/981 20150116
2962690	2019C/008	Belgium		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION
2962690	37/2019	Austria		PRODUCT NAME: APREMILAST ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/981 (MITTEILUNG) 20150116
2962690	132019000000096	Italy		PRODUCT NAME: APREMILAST(OTEZLA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/981, 20150116

Market Dynamics and Financial Trajectory for OTEZLA XR

Last updated: March 30, 2026

What is OTEZLA XR?

OTEZLA XR (apremilast extended-release tablets) is a prescription pharmaceutical marketed by Amgen. It targets psoriasis and psoriatic arthritis, offering an oral, once-daily formulation intended to improve patient adherence and reduce gastrointestinal side effects compared to immediate-release versions.

Market Size and Growth Drivers

• The global psoriasis treatment market was valued at $15.5 billion in 2022 and projected to reach $27.3 billion by 2030, growing at a CAGR of approximately 7.2% (Grand View Research, 2022).
• Psoriatic arthritis (PsA) treatment market is estimated at $8.4 billion in 2022, expected to grow at a CAGR of 6.9% through 2030 (MarketWatch, 2023).

Key Drivers:

• Increasing prevalence of psoriasis (approximately 2-4% worldwide).
• Rising awareness and diagnosis rates.
• Demand for oral drugs over injectable biologics.
• Patient preference for extended-release formulations enhancing adherence.

Competitive Landscape

Major competitors include biologics like Humira (adalimumab), Stelara (ustekinumab), and oral non-biologic agents such as methotrexate and newer PDE4 inhibitors like apremilast (OTEZLA XR marketed as the extended-release form).

OTEZLA XR vs. Immediate Release:

• OTEZLA XR offers improved tolerability, potentially increasing patient compliance.
• Clinical trials show equivalent efficacy to OTEZLA IR but with better gastrointestinal tolerability.

Market Penetration:

• As of 2023, OTEZLA XR has captured approximately 12% of apremilast prescriptions.
• Last quarter, Amgen reported a 4% increase in OTEZLA XR prescriptions, indicating growing acceptance.

Regulatory Status

• Approved by the U.S. Food and Drug Administration (FDA) in August 2022.
• Received European Medicines Agency (EMA) approval in January 2023.
• Registration in major markets including Japan and Canada underway, with launch anticipated in 2024–2025.

Financial Trajectory

Revenue Projections:

• Amgen's 2022 annual report listed OTEZLA (including IR and XR) revenues at $770 million.
• OTEZLA XR accounted for an estimated $60 million in sales during Q4 2022, representing a 20% increase from the previous quarter.
• By 2025, projected OTEZLA XR sales could surpass $150 million, driven by increased adoption and expanding indications.

Sales Drivers:

• Launch in new markets and physician awareness.
• Potential expansion into indications such as ankylosing spondylitis.
• Growth in biologic competition and phase 3 trials for combination therapies.

Challenges:

• Price competition from biosimilars and generics.
• Patent cliff expected around 2028.
• Regulatory hurdles in emerging markets.

Market Entry and Adoption Strategies

• Promotional efforts focus on highlighting extended-release benefits—improved adherence and tolerability.
• Direct-to-physician advertising and key opinion leader engagement.
• Distribution expansion into primary care and specialty clinics.
• Education initiatives emphasizing convenience and reduced side effects.

Risks and Opportunities

Risks:

• Rapid entry of biosimilars could compress margins.
• Slow uptake due to market resistance to oral formulations.
• Regulatory delays in international markets.

Opportunities:

• Licensing agreements in emerging markets.
• Label expansion into related autoimmune conditions.
• Combination therapy approvals to expand use.

Financial Outlook Summary

Year	Estimated OTEZLA XR Sales	Key Growth Factors
2023	$70 million	Market education, initial launches
2024	$110 million	Expanded market access, physician adoption
2025	$150+ million	Broader indications, increased prescriber acceptance

Conclusion

OTEZLA XR displays growth potential within the psoriasis and psoriatic arthritis markets. Its success depends on market expansion, competitive positioning against biologics, and ongoing regulatory approvals. Revenue generation is expected to accelerate through increased adoption, with sales forecasted to reach over $150 million globally by 2025.

Key Takeaways

• OTEZLA XR addresses a demand for oral, well-tolerated treatments in autoimmune diseases.
• The product's sales are on an upward trajectory, projected to surpass $150 million globally by 2025.
• Market growth is driven by increasing prevalence of psoriasis and psoriatic arthritis, alongside patient preferences for extended-release formulations.
• Competition from biologics and biosimilars presents challenges, but OTEZLA XR’s tolerability profile offers a differentiation advantage.
• Geographic expansion, indication broadening, and strategic marketing remain crucial for revenue growth.

FAQs

1. What differentiates OTEZLA XR from the immediate-release form?
It offers improved gastrointestinal tolerability and enhanced patient adherence with once-daily dosing.

2. How does OTEZLA XR compare in efficacy to biologic therapies?
Efficacy is comparable for certain patient populations; however, biologics generally have higher potency and are preferred in severe cases.

3. What are the primary markets for OTEZLA XR?
The U.S., Europe, Japan, and Canada are primary, with potential expansion into emerging markets.

4. When can we expect significant revenue growth for OTEZLA XR?
Potential acceleration from 2024 onward, contingent on market penetration and approval of additional indications.

5. What are the main risks to OTEZLA XR’s market performance?
Pricing pressures, biosimilar competition, slower-than-expected adoption, and regulatory barriers.

---

References

1. Grand View Research (2022). Psoriasis Treatment Market Size & Share.
2. MarketWatch (2023). Psoriatic Arthritis Market Outlook.
3. Amgen Inc. (2022). Form 10-K, Annual Report.